---
document_datetime: 2023-09-21 16:59:51
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/rotarix-epar-procedural-steps-taken-authorisation_en.pdf
document_name: rotarix-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.4177224
conversion_datetime: 2025-12-19 21:23:06.751327
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant GlaxoSmithKline Biologicals S.A. submitted on 2 December 2004 an application for Marketing  Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Rotarix,  through  the centralised procedure. The eligibility to the centralised procedure was agreed upon by the EMEA/CHMP on 19 November 2004.

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: P. Neels

## Licensing status:

Rotarix has been given a Marketing Authorisation in Mexico on 12 July 2004.

## 2. Steps taken for the assessment of the product

- The application was received by the EMEA on 2 December 2004.
- The procedure started on 20 December 2004.
- The Rapporteur's first Assessment Report was circulated to all  CHMP  members  on 2 March 2005.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP members on 1 March 2005.
- The BWP during its meeting of 11-13 April 2005 adopted the BWP Report to be transmitted to the CHMP for endorsement.
- During the meeting on 18-21 April, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 21 April 2005.
- The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 9 August 2005.
- The summary report of the inspection carried out at the manufacturing site Rixensart on 1 June 2005 was issued on 8 August 2005.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on  22 September 2005.
- During  the  CHMP  meeting  on  13  October  2005,  the  CHMP  agreed  on  a  list  of  outstanding issues to be addressed in writing by the applicant.
- The applicant submitted the responses to the CHMP  list of outstanding issues on 4 November 2005.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of outstanding issues to all CHMP members on  25 November 2005.
- During  the  meeting  on  13-14  December  2005,  the  CHMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting a Marketing Authorisation to Rotarix on 14 December 2005.
- The CHMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 21 February 2006.

Co-Rapporteur: E. Skovlund